Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
VYVGART® SC is first and only neonatal Fc receptor blocker approved to treat CIDPAuthorization is based on global ADHERE study,...
Piper Sandler analyst Allison Bratzel maintains argenx (NASDAQ:ARGX) with a Overweight and raises the price target from $820...
TD Cowen analyst Yaron Werber maintains argenx (NASDAQ:ARGX) with a Buy and raises the price target from $800 to $1146.
RBC Capital analyst Luca Issi maintains argenx (NASDAQ:ARGX) with a Outperform and raises the price target from $850 to $860.
Evercore ISI Group analyst Gavin Clark-Gartner maintains argenx (NASDAQ:ARGX) with a Outperform and raises the price target ...
HC Wainwright & Co. analyst Douglas Tsao maintains argenx (NASDAQ:ARGX) with a Buy and raises the price target from $774...
argenx (NASDAQ:ARGX) reported quarterly earnings of $5.18 per share which beat the analyst consensus estimate of $4.30 by 20.44...
